Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01579279 · ClinicalTrials.gov registry record · Phase 2
A Study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain
A Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT01579279 is a Phase 2 study that was terminated before completion, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 1 participants.
The verdict
NCT01579279, a Phase 2 study, was terminated before completion, sponsored by AbbVie (prior sponsor, Abbott).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
To evaluate the safety and efficacy of ABT-652 compared to Placebo in subjects with diabetic neuropathic pain. People with diabetes can, over time develop nerve damage throughout the body with symptoms such as pain, tingling, or numbness (loss of feeling) in the hands, arms, feet and legs.
Interventions
- DRUG Placebo
- DRUG Duloxetine
- DRUG ABT-652 6 mg
- DRUG ABT-652 12 mg
- DRUG ABT-652 12 mg - 18 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2012-04 |
| Est. Completion | 2012-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01579279
The ClinicalTrials.gov registry entry for NCT01579279 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01579279 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01579279 about?
NCT01579279 is a clinical study titled "A Study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain". To evaluate the safety and efficacy of ABT-652 compared to Placebo in subjects with diabetic neuropathic pain. People with diabetes can, over time develop nerve damage throughout the body with symptoms such as pain, tingling, or numbness (loss of feeling) in the hands, arms, feet and legs.
What is the current status of trial NCT01579279?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2012-04. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01579279?
The interventions under investigation include: Placebo (DRUG), Duloxetine (DRUG), ABT-652 6 mg (DRUG), ABT-652 12 mg (DRUG), ABT-652 12 mg - 18 mg (DRUG).
Who is sponsoring clinical trial NCT01579279?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.